Literature DB >> 27872940

Cholestyramine as monotherapy for Graves' hyperthyroidism.

Chaozer Er1, Ashish Anil Sule1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27872940      PMCID： PMC5331142          DOI： 10.11622/smedj.2016177

Source DB:  PubMed          Journal:  Singapore Med J        ISSN： 0037-5675            Impact factor:   1.858


× No keyword cloud information.
  6 in total

1.  Low doses of cholestyramine in the treatment of hyperthyroidism.

Authors:  Mahmoud Ali Kaykhaei; Mesbah Shams; Abdosamad Sadegholvad; Mohammad Hossein Dabbaghmanesh; Gholamhossein Ranjbar Omrani
Journal:  Endocrine       Date:  2008-10-23       Impact factor: 3.633

2.  Cholestyramine for thyrotoxicosis?

Authors:  Dagmar Lin; Nuntra Suwantarat; Michael Bornemann
Journal:  J Fam Pract       Date:  2013-04       Impact factor: 0.493

3.  Light symptoms following a high-dose intentional L-thyroxine ingestion treated with cholestyramine.

Authors:  D A de Luis; A Dueñas; J Martin; L Abad; L Cuellar; R Aller
Journal:  Horm Res       Date:  2002

4.  The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.

Authors:  Wen-Chin Tsai; Dee Pei; Tso-Fu Wang; Du-An Wu; Jer-Chuan Li; Cheng Lian Wei; Chien-Hsing Lee; Sheng-Pyng Chen; Shi-Wen Kuo
Journal:  Clin Endocrinol (Oxf)       Date:  2005-05       Impact factor: 3.478

Review 5.  Role of Cholestyramine in Refractory Hyperthyroidism: A Case Report and Literature Review.

Authors:  Khaled A Alswat
Journal:  Am J Case Rep       Date:  2015-07-24

6.  Carbimazole-induced agranulocytosis.

Authors:  Anisha Mohan; Siby Joseph; Neeraj Sidharthan; Dhanya Murali
Journal:  J Pharmacol Pharmacother       Date:  2015 Oct-Dec
  6 in total
  1 in total

1.  Lipocrinology - the relationship between lipids and endocrine function.

Authors:  Sanjay Kalra; Gagan Priya
Journal:  Drugs Context       Date:  2018-01-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.